Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +120% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: DKK 309.1B (to FY2025). Net Income: DKK 102.4B, trailing twelve months to FY2025. Free Cash Flow: DKK 59.0B, trailing twelve months to FY2025. Op Margin: 41%, trailing twelve months to FY2025.

NVONovo Nordisk A/S

HealthcareUSD

$47.19

$34.7652 weeks$61.72

NVO as reported

Novo Nordisk A/S reported DKK 309.1B of revenue over the trailing twelve months, +120% on the year before. 10 reported series are charted on this page, each one as filed.

DKK 309.1B

Revenue, trailing twelve months · to FY2025 · +120% against the twelve months before

Net Income: DKK 102.4B
Net Income · +114% year on year · trailing twelve months to FY2025
Free Cash Flow: DKK 59.0B
Free Cash Flow · +21% year on year · trailing twelve months to FY2025
Op Margin: 41%
Op Margin · trailing twelve months to FY2025

Every series Ryufin has for NVO, trailing twelve months
Series	Latest	Year on year	As of
Revenue	DKK 309.1B	+120%	FY2025
Net Income	DKK 102.4B	+114%	FY2025
EPS	DKK 23.03	+122%	FY2025
Gross Margin	81%	n/a	FY2025
Op Margin	41%	n/a	FY2025
Net Margin	33%	n/a	FY2025
ROE	53%	n/a	FY2025
ROA	19%	n/a	FY2025
ROIC	33%	n/a	FY2025
Free Cash Flow	DKK 59.0B	+21%	FY2025